References
- 1. Mikhailov TA, Furner SE. Breastfeeding and genetic factors in the etiology of inflammatory bowel disease in children. World J Gastroenterol. 2009;15:270-9.10.3748/wjg.15.270
- 2. Danese S, Sans M, Fiocchi C. Inflammatory bowel disease: the role of environmental factors. 2004;3:394-400.
- 3. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002; 347:417-29.10.1056/NEJMra020831
- 4. Baumgart DC, Sandborn WJ, Inflammatory bowel disease: clinical aspects and established and evolving treatments. The Lancet. 2007;369(9573):1641-57.10.1016/S0140-6736(07)60751-X
- 5. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280-8.10.3748/wjg.14.4280273117718666314
- 6. Heyman MB, Kirschner BS, Gold BD, Ferry G, Baldassano R, Cohen SA, et al., Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr. 2005;146:35-40.10.1016/j.jpeds.2004.08.04315644819
- 7. Rioux JD, Xavier RJ, Taylor KD, Silverberg MS, Goyette P, Huett A, et al. Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet. 2007;39(5):596-604.10.1038/ng2032275793917435756
- 8. Tsianos EV, Katsanos KH, Tsianos VE. Role of genetics in the diagnosis and prognosis of Crohn‘s disease. World J Gastroenterol. 2012;18(2):105-18.10.3748/wjg.v18.i2.105325743722253516
- 9. Tanida S, Mizoshita T, Ozeki K, Katano T, Kataoka H, Kamiya T, Joh T, Advances in refractory ulcerative colitis treatment: A new therapeutic target, Annexin A2. World J Gastroenterol. 2015;21(29):8776-86.10.3748/wjg.v21.i29.8776452802026269667
- 10. Zhang X, Song L, Li L, Zhu B, Huo L, Hu Z, et al. Phosphatidylserine externalized on the colonic capillaries as a novel pharmacological target for IBD therapy. Sig Transduct Target Ther. 2021;6:235.10.1038/s41392-021-00626-z820621234131110
- 11. Ford AC, Bernstein CN, Khan KJ, Abreu MT, Marshall JK, Talley NJ, et al. Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol. 2011;106(4),590-9.
- 12. Marehbian J, Arrighi HM, Hass S, Tian H, Sandborn WJ. Adverse events associated with common therapy regimens for moderate-to-severe Crohn’s disease. Am J Gastroenterol. 2009;104(10):2524-33.10.1038/ajg.2009.32219532125
- 13. Clark WM, Hazel JS, Coull BM. Lazaroids. Drugs. 1995;50:971-83.10.2165/00003495-199550060-00005
- 14. De Oca J, Guadrado S, Vallet J, Banasco C, Martin E, Ardanuy C, et al. Protective effects of lazaroid U74389G on intestinal graft after heterotopic small bowel transplantation in rats. J Sur Res. 1998;75(1):18-23.10.1006/jsre.1997.5244
- 15. Kavanagh RJ, Kam PCA Lazaroids: efficacy and mechanism of action of the 21-aminosteroids in neuroprotection. Br J Anaesth. 200;86(1):110-19.10.1093/bja/86.1.110
- 16. Cahill L, Hall ED. Is it time to resurrect “Lazaroids”? J Neurosci Res. 2017;95:17-20.
- 17. Chalasti M, IordanouC, Kratiras Z, Stylianaki A, Trigka E-A, Lakiotaki E, et al. Experimental isolation and preservation of solid organs before transplantation: effects of pretreatment using four different molecules. J Int Med Res. 2020;48(6):1-19.10.1177/0300060520933452
- 18. Morris GP, Beck PL, Herridge MS, Depew W, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat. Gastroenterol. 1989; 96:795-803.10.1016/0016-5085(89)90904-9
- 19. Wallace JL, Le T, Carter L, Appleyard CB, Beck PL. Hapten-induced chronic colitis in the rat: alternatives to trinitrobenzene sulfonic acid. J Pharmacol Toxicol Methods. 1995;33(4):237-9.10.1016/1056-8719(95)00001-X
- 20. Stavreva G, Shopova V, Dancheva V, Stoynova A, Terziev L. Effect of 21-aminosteroid U-74389G on markers for pneumotoxicity in rat bronchoalveolar lavage flid after intratracheal amiodarone administration. J Biomed Clin Res. 2008;1(1):30-9.
- 21. Stavreva GT, Dancheva VY, Terziev LG, Krastev PK. Effects of 21-aminosteroid U-74389G on amiodarone-induced pulmonary toxicity in rats. Arch Balk Med Union. 2019;54(3):404-10.10.31688/ABMU.2019.54.3.01
- 22. Antonioli L, Fornai M, Colucci R, Ghisu N, Da Settimo F, Natale G et al. Inhibition of adenosine deaminase attenuates inflammation in experimental colitis. J Pharmacol Exp Ther. 2007;322:435-42.10.1124/jpet.107.12276217488880
- 23. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: pharmacological targets and novel treatments. J Neurogastroenterol Motil. 2016;22(4):558-74.10.5056/jnm16001505656627431236
- 24. Piechota-Polanczyk A, Fichna J. Review article: the role of oxidative stress in pathogenesis and treatment of inflammatory bowel diseases. Naunyn Schmiedebergs Arch Pharmacol. 2014;387(7):605-20.10.1007/s00210-014-0985-1406533624798211
- 25. Kim JJ, Shajib MS, Manocha MM, Khan WI. Investigating intestinal inflammation in DSS-induced model of IBD. J Vis Exp. 2012;(60):3678.10.3791/3678
- 26. Sanchez-Muñoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. Role of cytokines in inflammatory bowel disease. World J Gastroenterol. 2008;14(27):4280-8.10.3748/wjg.14.4280
- 27. Das KM, Farag SA. Current medical therapy of inflammatory bowel disease. World J Gastroenteroi. 2000; 6(4):483-9.
- 28. Hayashi R, Wada H, Ito K, Adcock I. Effects of glucocorticoids on gene transcription. Eur J Pharmacol 2004;500(1-3):51-62.10.1016/j.ejphar.2004.07.011
- 29. Braughler JM, Chase RL, Neff GL, Yonkers PA, Day JS, Hall ED, et al. A new 21-aminosteroid antioxidant lacking glucocorticoid activity stimulates adrenocorticotropin secretion and blocks arachidonic acid release from mouse pituitary tumor (AtT-20) cells. J Pharmacol Exp Ther. 1988;244(2):423-7.
- 30. Jacobsen EJ, McCall JM, Ayer DE, Van dootnik FJ, Palmer JR, Belonga KL, et al. Novel 21-aminosteroids that inhibit iron-dependent peroxidation and protect against nervous system trauma. Journal of Medicinal Chemistry. 1990;33(4): 1145-51.10.1021/jm00166a010
- 31. Hall ED, Mccall JM, Means ED. Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and subarachnoid hemorrhage. Adv Pharmacol. 1994;28:221-68.10.1016/S1054-3589(08)60497-4
- 32. Muller TB, Haraldseth O, Jones R.A., et al. Perfusion and diffusion-weighted MR images for in vivo evaluation of treatment with U74389G in a rat stroke model. Stroke 1995; 26(8):1453-8.10.1161/01.STR.26.8.1453
- 33. Fabian RH, Dewitt DS, Kent TA. The 21-aminosteroid U-74389G reduces cerebral superoxide anión concentration following fluid percussion injury of the brain. J neurotrauma. 1998;15(6):433-40.10.1089/neu.1998.15.433
- 34. Shi F, Cavitt J, Audus KL. 21-aminosteroid and 2-(aminomethyl) chromans inhibition of arachidonic acid-induced lipid peroxidation and permeability enhancement in bovine brain microvessel endothelial cell monolayers. Free Radie Biol Med. 1995; 19(3):349-57.10.1016/0891-5849(95)00049-4
- 35. Antonini JM, Van DK, Dimatteo M, Rea Sor MJ. Attenuation of acute inflammatory effects of silica in rat lung by 21-aminosteroid, U74389G. Inflammation. 1995; 19(1):9-21.10.1007/BF015343767705890
- 36. Remmers D, Wenger A, Grotz M, Seekamp A, Pape HC, Gruner A, et al. Attenuation of mutliple organ dysfunction in a chronic sheep model by the 21-aminosteroid U74389G. J Surg Res. 1996;62(2):278-83.10.1006/jsre.1996.02088632652
- 37. Huang H, Patel PB, Salahudeen AK. Lazaroid compounds prevent early but not late stages of oxidant-induced cell injury: potential explanation for the lack of efficacy of lazaroids in clinical trials. Pharmacol Res. 2001;43(1):55-61.10.1006/phrs.2000.074011207066
- 38. Kawarski M, Thomas K Hagerman TK, Caitlin E Karver CE. Lazaroids U83836E and U74389G are potent, time-dependent inhibitors of caspase-1. Chem Biol Drug Des. 2015; 86(5):1049-54.10.1111/cbdd.1257225871734